Ifinatamab deruxtecan
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Metastatic Solid Tumors
Conditions
Recurrent or Metastatic Solid Tumors
Trial Timeline
Apr 10, 2024 → Jul 25, 2028
NCT ID
NCT06330064About Ifinatamab deruxtecan
Ifinatamab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Recurrent or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06330064. Target conditions include Recurrent or Metastatic Solid Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06330064 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent or Metastatic Solid Tumors